Earnings Beat: Castle Biosciences, Inc. (NASDAQ:CSTL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Castle Biosciences(CSTL.US) Q1 2024 Earnings Conference
The following is a summary of the Castle Biosciences, Inc. (CSTL) Q1 2024 Earnings Call Transcript:Financial Performance:Castle Biosciences reported Q1 2024 revenue increase of 74% to $73 million, lar
Castle Biosciences, Inc. (CSTL) Q1 2024 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) Q1 2024 Earnings Call Transcript
Castle Biosciences' Growth at Risk: How Loan Terms Could Hamper Business Agility
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Castle Biosciences (CSTL)
Castle Biosciences Says New Data Supporting The Utility Of Its DecisionDx-SCC Test In Patients With High-risk Cutaneous Squamous Cell Carcinoma Tumors Located On The Head And Neck (H&N) Will Be Shared At 56Th American College Of MOHS Surgery Meeting
Castle Biosciences Says New Data Supporting The Utility Of Its DecisionDx-SCC Test In Patients With High-risk Cutaneous Squamous Cell Carcinoma Tumors Located On The Head And Neck (H&N) Will Be Shared
Castle Biosciences Is Maintained at Outperform by Baird
Castle Biosciences Is Maintained at Outperform by Baird
DecisionDx-SCC Significantly Improves Prediction Accuracy of Metastatic Events After Mohs Surgery in New Study of Patients With High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that new data supporting the utility of its DecisionDx-SCC test in patients with
Baird Maintains Outperform on Castle Biosciences, Raises Price Target to $34
Baird analyst Catherine Ramsey maintains Castle Biosciences with a Outperform and raises the price target from $33 to $34.
Castle Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 46.24% Baird $33 → $34 Maintains Outperform 03/01/2024 20.43% Keybanc $25 → $28 Maintains Overw
Castle Biosciences Increases FY23 Revenue From $235M-$240M To $255M-$265M Vs $237.636M Est.
Castle Biosciences Increases FY23 Revenue From $235M-$240M To $255M-$265M Vs $237.636M Est.
Castle Biosciences Q1 2024 GAAP EPS $(0.09) Beats $(0.33) Estimate, Sales $72.974M Beat $66.199M Estimate
Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.33) by 72.73 percent. The company reported quarterly sales of $72.974
Castle Biosciences Unveils Informative Management Presentation Slides
Earnings Flash (CSTL) CASTLE BIOSCIENCES Posts Q1 Revenue $73M, Vs. Street Est of $66.2M
04:15 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (CSTL) CASTLE BIOSCIENCES Posts Q1 Revenue $73M, vs. Street Est of $66.2M
Press Release: Castle Biosciences Reports First Quarter 2024 Results
Castle Biosciences Reports First Quarter 2024 Results Q1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue
Castle Biosciences 1Q Rev $73M >CSTL
Castle Biosciences 1Q Rev $73M >CSTL
Castle Biosciences Reports First Quarter 2024 Results
Q1 2024 revenue increased 74% over Q1 2023 to $73 millionQ1 2024 total test reports increased 40% over Q1 2023Raising full-year 2024 revenue guidance to $255-265 million from $235-240 millionConferenc
Castle Biosciences(CSTL.US) Officer Sells US$22,642.73 in Common Stock
$Castle Biosciences(CSTL.US)$ Officer MAETZOLD DEREK J sold 1,126 shares of common stock on Apr 23, 2024 at an average price of $20.109 for a total value of $22,642.73.Source: Announcement What is sta
We're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash Burn
No Data